We are live on
!
Find out more
Atara Biotherapeutics
ATRA
ATRA
140 hedge funds and large institutions have $1.06B invested in Atara Biotherapeutics in 2020 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 52 increasing their positions, 37 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
136% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 14
126% more call options, than puts
Call options by funds: $1.76M | Put options by funds: $778K
41% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 37
15% more funds holding
Funds holding: 122 → 140 (+18)
0.1% more ownership
Funds ownership: 4.34% → 4.44% (+0.1%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
6% less capital invested
Capital invested by funds: $1.13B → $1.06B (-$65.6M)
Holders
140
Holders Change
+18
Holders Change %
+14.75%
% of All Funds
2.82%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
33
Increased
52
Reduced
37
Closed
14
Calls
$1.76M
Puts
$778K
Net Calls
+$983K
Net Calls Change
+$227K
Top Buyers
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$29.7M |
| 2 |
JP Morgan Chase
New York
|
+$19.4M |
| 3 |
BlackRock
New York
|
+$10.4M |
| 4 |
Morgan Stanley
New York
|
+$7.25M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
+$5.81M |
Top Sellers
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$11.3M |
| 2 |
CCM
Consonance Capital Management
New York
|
-$7.53M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$6.77M |
| 4 |
SPC
Slate Path Capital
New York
|
-$6.12M |
| 5 |
Goldman Sachs
New York
|
-$4.92M |
